Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1037967

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	CJD
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve diagnosis rates of sporadic Creutzfeldt-Jakob disease.
	tabling member constituency	Witham
	tabling member printed	Priti Patel
	uin	206318
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206320 206323 206326 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
	tabling member	4066 label Biography information for Priti Patel

1037969

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	CJD
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the symptoms of sporadic Creutzfeldt-Jakob disease are identified at the earliest opportunity.
	tabling member constituency	Witham
	tabling member printed	Priti Patel
	uin	206320
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206318 206323 206326 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
	tabling member	4066 label Biography information for Priti Patel

1037974

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	CJD
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people were diagnosed with sporadic Creutzfeldt-Jakob Disease in (a) Witham constituency, (b) the East of England and (c) England and Wales in the most recent five years for which data is available.
	tabling member constituency	Witham
	tabling member printed	Priti Patel
	uin	206323
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206318 206320 206326 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
	tabling member	4066 label Biography information for Priti Patel

1037977

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	CJD
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to raise awareness among medical professionals of the symptoms of (a) sporadic, (b) variant, (c) genetic and (d) Iatrogenic Creutzfeldt-Jakob Disease.
	tabling member constituency	Witham
	tabling member printed	Priti Patel
	uin	206326
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206318 206320 206323 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
	tabling member	4066 label Biography information for Priti Patel

1037985

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	CJD
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the average waiting time has been for a diagnosis of sporadic Creutzfeldt-Jakob Disease (CJD) in the last five years for which data is available.
	tabling member constituency	Witham
	tabling member printed	Priti Patel
	uin	206327
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206318 206320 206323 206326 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
	tabling member	4066 label Biography information for Priti Patel

1039611

	registered interest
	date	11/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prisons: Alcoholic Drinks and Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the number of prisoners who have reported a drug or alcohol misuse problem upon arrival at prison in the latest period for which figures are available.
	tabling member constituency	Vale of Clwyd
	tabling member printed	Chris Ruane
	uin	207567
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Data on alcohol and drug misuse treatment in prisons and other secure settings is available from Public Health England’s national drug treatment monitoring system (NDTMS). The 2016-17 NDTMS report shows that there were 59,258 adults in contact with drug and alcohol treatment services within secure settings. Most of these (55,721) were in prisons, but there were also 3,015 in young offender institutions and 522 in immigration and removal centres. This report can be viewed at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/statistics/substance-misuse-treatment-in-secure-settings-statistics-2016-to-2017" target="_blank">https://www.gov.uk/government/statistics/substance-misuse-treatment-in-secure-settings-statistics-2016-to-2017</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 16/01/2019 17:22:23 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	534 label Biography information for Chris Ruane

1039613

	registered interest
	date	11/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Social Services: Disability
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the forthcoming social care green paper will address social care provision for adults of working age with a disability.
	tabling member constituency	Vale of Clwyd
	tabling member printed	Chris Ruane
	uin	207569
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>The Green Paper will cover care and support for adults of all ages, and incorporate insights from the joint work the Department of Health and Social Care has done with the Ministry of Housing, Communities and Local Government on working age adults with care and support needs.</p><p> </p><p>The joint work undertaken by the Department of Health and Social Care and the Ministry of Housing, Communities and Local Government last year engaged widely with stakeholders; including local authorities, providers, national charities and system partners as well as people with lived experience, family members and organisations run by disabled people such as DRUK and Inclusion London. Officials have also collated and reviewed existing reports and evidence previously produced by voluntary sector organisations and other partners as part of this work.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 16/01/2019 12:25:07 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	534 label Biography information for Chris Ruane

1039594

	registered interest
	date	11/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Department of Health and Social Care: Brexit
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much money his Department has allocated for preparations for the UK leaving the EU without a deal to date; how much of that funding has been made by way of ministerial direction; and for what functions that funding has been allocated.
	tabling member constituency	Twickenham
	tabling member printed	Sir Vince Cable
	uin	207547
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>At Autumn Budget 2017, HM Treasury made an additional £3 billion of funding available over the next two years – £1.5 billion in each year – so that departments and the devolved administrations can continue to prepare effectively for European Union exit.</p><p> </p><p>That is in addition to the £700 million previously made available to prepare for EU exit at Autumn Budget 2016.</p><p> </p><p>In the Spring Statement on 13 March 2018, my Rt. hon. Friend the Chief Secretary to the Treasury (Elizabeth Truss MP) laid a Written Ministerial Statement, <a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-statements/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=HCWS540" target="_blank">HCWS540</a>, setting out the full Departmental allocations of the £1.5 billion for 2018/19.</p><p> </p><p>HM Treasury approved £21.1 million of funding for the Department of Health and Social Care’s preparations for EU exit in 2018/19, including planning for ‘no deal’. Spend against this allocation for 2018/19 will be included in the 2018/19 financial accounts in due course.</p><p> </p><p>The Autumn Budget 2018 confirmed an additional £500 million of cross-Government funding for 2019/20, meaning the Government will have invested over £4 billion in preparing for EU exit since 2016. This funding will help departments manage pressures and contingencies arising from EU exit preparations which fall in the 2019/20 financial year, as well as ensuring that the United Kingdom is prepared to seize the opportunities available when we leave the EU. The Department of Health and Social Care has been allocated £50 million from this budget, as set out in the Chief Secretary’s Written Ministerial Statement <a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-statements/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=HCWS1205" target="_blank">HCWS1205</a>, laid before Parliament on the 19 December 2018.</p><p> </p><p>No written ministerial direction for expenditure on contingency planning for ‘no deal’ has been sought by the Accounting Officer for the Department.</p><p> </p><p>The Department is preparing for all eventualities and the resources available to support preparations are kept under constant review.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 16/01/2019 12:40:06 answering member 1585 label Biography information for Stephen Hammond
	tabling member	207 label Biography information for Sir Vince Cable

1037778

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Air Pollution
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 October 2018 to Question 174612 on Air Pollution, what plans his Department has to further study the effects of PM0.1 and PM1 particles on human health.
	tabling member constituency	Stroud
	tabling member printed	Dr David Drew
	uin	206215
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Recent assessments have been undertaken of the health effects of long-term exposure to the air pollution mixture in the United Kingdom, but no separate assessments of the impact of the PM1 and PM0.1 components (particulate matter with an aerodynamic diameter smaller than 1 or 0.1 microns, respectively) of particulate air pollution have been produced.</p><p> </p><p>The reviews by the Health Effects Institute and the World Health Organization about the effects of different components of air pollution, including ultrafine particles (PM0.1), concluded that there is currently limited evidence on the effects on health of ultrafine particles. These reviews are available at the following link:</p><p> </p><p><a href="https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles" target="_blank">https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles</a></p><p> </p><p><a href="http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1" target="_blank">http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1</a></p><p> </p><p>Currently, Public Health England has no plans to engage in work on the effects of PM1 and PM0.1 particles on human health over the coming year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2019 12:30:56 answering member 4067 label Biography information for Steve Brine
	tabling member	252 label Biography information for Dr David Drew

1037779

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Public Health: Fuel Poverty
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the effects of fuel poverty on public health.
	tabling member constituency	Stroud
	tabling member printed	Dr David Drew
	uin	206216
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>The causes of excess winter death and illness are complex and interlinked, and include circulating diseases such as influenza, cold temperatures and wider determinants of health, such as poor housing and fuel poverty. It is difficult to attribute the relative impacts of each of these factors as the contribution varies year on year.</p><p> </p><p>Living in a cold home and being in fuel poverty represent a significant risk to health, wellbeing and inequalities. The joint Public Health England and University College London Institute of Health Equity report ‘Local action on health inequalities: Fuel poverty and cold home-related health problems’ reported that an estimated 21.5% of annual excess winter deaths are attributable to the coldest quarter of housing. The report is available to view at the following link:</p><p> </p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/355790/Briefing7_Fuel_poverty_health_inequalities.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/355790/Briefing7_Fuel_poverty_health_inequalities.pdf</a></p><p> </p><p>The Public Health Outcomes Framework (PHOF) includes an Excess Winter Deaths Index and a Fuel Poverty indicator, available to view at the following link:</p><p> </p><p><a href="https://fingertips.phe.org.uk/search/fuel%20poverty#page/3/gid/1/pat/6/par/E12000007/ati/102/are/E09000022/iid/90356/age/1/sex/4" target="_blank">https://fingertips.phe.org.uk/search/fuel%20poverty#page/3/gid/1/pat/6/par/E12000007/ati/102/are/E09000022/iid/90356/age/1/sex/4</a></p><p> </p><p>Local government use PHOF to assess the scale of the problem locally and are supported to take action through both the Cold Weather Plan for England and the National Institute for Health and Care Excellence Guidelines.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2019 12:28:53 answering member 4067 label Biography information for Steve Brine
	tabling member	252 label Biography information for Dr David Drew